Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment

K. Chan, A. E. Clarke, R. Ramsey-Goldman, W. Foulkes, B. Tessier Cloutier, M. B. Urowitz, D. Gladman, O. Nived, J. Romero-Diaz, M. Petri, E. Ginzler, P. R. Fortin, S. C. Bae, D. J. Wallace, E. H. Yelin, Sasha Bernatsky

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Objective: There is a decreased risk of breast cancer in systemic lupus erythematosus (SLE) versus the general population; little is known regarding the receptor status of breast cancers in SLE, or treatment. Methods: Breast cancer cases occurring after SLE diagnosis were ascertained through linkage with tumor registries. We determined breast cancer positivity for estrogen receptors (ER), progesterone receptors (PR), and/or Human Epidermal Growth Factor Receptor 2 (HER2), as well as cancer treatment. Results: We obtained information on ER, PR, and/or HER2 status for 63 SLE patients with breast cancer. Fifty-three had information on ER and/or PR status; 36 of these (69%) were ER positive. Thirty-six of the 63 had information on HER2 status; of these, 26 had complete information on all three receptors. Twenty-one of these 26 (81%) were HER2 negative; seven of 26(27%) were triple negative. All but one patient underwent surgery; 11.5% received both non-tamoxifen chemotherapy and radiotherapy, 16.4% radiotherapy without non-tamoxifen chemotherapy, and 14.7% received non-tamoxifen chemotherapy without radiotherapy. Conclusion: ER positivity was similar to historical general population figures, with a trend toward a higher proportion of triple-negative breast cancers in SLE (possibly reflecting the relatively young age of our SLE patients).

Original languageEnglish (US)
Pages (from-to)120-123
Number of pages4
Issue number1
StatePublished - Jan 1 2018


  • Breast cancer
  • estrogen
  • progesterone
  • receptor
  • systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment'. Together they form a unique fingerprint.

Cite this